Latest news with #CarismaTherapeutics
Associated Press
6 hours ago
- Business
- Associated Press
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, GNTY on Behalf of Shareholders
NEW YORK, June 27, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Carisma Therapeutics Inc. (NASDAQ: CARM)'s merger with OrthoCellix, Inc. Upon completion of the proposed transaction, existing Carisma shareholders are expected to own approximately 10% of the combined company. If you are a Carisma shareholder, click here to learn more about your legal rights and options. Enzo Biochem, Inc. (OTCMKTS: ENZB)'s sale to Battery Ventures for $0.70 per share in cash. If you are an Enzo shareholder, click here to learn more about your rights and options. Guaranty Bancshares, Inc. (NYSE: GNTY)'s sale to Glacier Bancorp, Inc. for 1.0000 share of Glacier stock for each Guaranty share (subject to adjustment under certain circumstances). If you are a Guaranty shareholder, click here to learn more about your rights and options. Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected]. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Halper Sadeh LLC Daniel Sadeh, Esq. Zachary Halper, Esq. (212) 763-0060 [email protected] [email protected] View original content to download multimedia: SOURCE Halper Sadeh LLP
Associated Press
14 hours ago
- Business
- Associated Press
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
BALA CYNWYD, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847. There is no cost or financial obligation to you. Carisma Therapeutics Inc. (Nasdaq - CARM) Under the terms of the Merger Agreement, Carisma will be acquired by OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Nasdaq - OCGN). Upon the closing of the proposed transactions, existing Carisma stockholders are expected to own approximately 10% of the combined company. The investigation concerns whether the Carisma Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company's shareholders in the combined entity. Additional information can be found at Guaranty Bancshares, Inc. (NYSE - GNTY) Under the terms of the agreement, Guaranty will be acquired by Glacier Bancorp, Inc. ('Glacier') (NYSE - GBCI). Guaranty shareholders are to receive 1.0000 share of Glacier stock for each Guaranty share. Based on the closing price of $41.58 for Glacier shares on June 23, 2025, the transaction would result in aggregate consideration of $476.2 million and value of $41.58 per Guaranty share. The investigation concerns whether the Guaranty Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company's shareholders. Additional information can be found at MRC Global Inc. (NYSE - MRC) Under the terms of the Merger Agreement, MRC will be acquired by DNOW Inc. ('DNOW') (NYSE - DNOW). MRC shareholders will receive 0.9489 shares of DNOW common stock for each share of MRC common stock. Upon completion of the transaction, DNOW and MRC shareholders will respectively own approximately 56.5% and approximately 43.5% of the combined company on a fully diluted basis. The investigation concerns whether the MRC Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company's shareholders in the combined entity. Additional information can be found at Turnstone Biologics Corp. (Nasdaq - TSBX) Under the terms of the agreement, Turnstone will be acquired by XOMA Royalty Corporation ('XOMA Royalty') (Nasdaq - XOMA) for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right ('CVR'). The investigation concerns whether the Turnstone Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Additional information can be found at Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Business Insider
12-06-2025
- Business
- Business Insider
Carisma Therapeutics Stock (CARM) Retreats 35% After a Massive Rally
Carisma Therapeutics (CARM) stock retreated on Wednesday after the biopharmaceutical company's shares underwent a massive 389.42% rally on Tuesday. There was no clear news behind this surge, making an argument for it being a 'dead cat bounce' or 'sucker's rally.' Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Adding to this is the state of Carisma Therapeutics' operations. The company has laid off a large portion of its staff and is considering strategic alternatives. Management has even warned that a wind-down of the business could be on the horizon. With the lack of a catalyst and the dire situation Carisma Therapeutics is in, traders shouldn't be surprised to learn that the stock is falling after yesterday's rally. This has CARM shares down 35.1% in pre-market trading today. While Carisma Therapeutics has retained a large portion of its gains from yesterday, that could diminish further over the next few days of trading. Is Carisma Therapeutics Stock a Buy, Sell, or Hold? TipRanks' AI analyst, Spark, offers a Neutral (43) rating and no price target for Carisma Therapeutics. Spark cites 'significant financial challenges' including 'poor financial performance and valuation metrics' as reasons for this rating.
Business Insider
11-06-2025
- Business
- Business Insider
Is the 250% Carisma Therapeutics Stock (CARM) Surge a Sucker's Rally?
Carisma Therapeutics (CARM) stock underwent a massive rally on Tuesday despite a lack of news from the biopharmaceutical company. This may have investors wondering what's going on with CARM stock today. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter It appears that Carisma Therapeutics stock saw a 'sucker's rally' or 'dead cat bounce' today. This is when a stock that has suffered strong negative momentum undergoes an unexpected rally. While that might see some traders take interest in CARM stock, they should first note that the company is considering strategic alternatives, including the potential wind-down of its operations. CARM stock was up 247.71% during pre-market trading on Tuesday. However, the stock has dropped 46% year-to-date and 81.71% over the past 12 months. Is Carisma Therapeutics Stock a Buy, Sell, or Hold? Spark, TipRanks' AI analyst, rates Carisma Therapeutics stock an Underperform (40) with no price target. The company faces 'significant financial challenges, as evidenced by its poor financial performance and valuation metrics.'
